Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

About Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADMS
  • CUSIP: N/A
  • Web: www.adamaspharma.com
Capitalization:
  • Market Cap: $481.13 million
  • Outstanding Shares: 22,514,000
Average Prices:
  • 50 Day Moving Avg: $18.21
  • 200 Day Moving Avg: $17.22
  • 52 Week Range: $12.10 - $23.84
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.76
  • P/E Growth: -0.07
Sales & Book Value:
  • Annual Revenue: $177,000.00
  • Price / Sales: 2,718.22
  • Book Value: $4.63 per share
  • Price / Book: 4.62
Profitability:
  • EBIDTA: ($66,610,000.00)
  • Net Margins: -10,499.65%
  • Return on Equity: -52.91%
  • Return on Assets: -45.76%
Debt:
  • Debt-to-Equity Ratio: 0.32%
  • Current Ratio: 11.79%
  • Quick Ratio: 11.79%
Misc:
  • Average Volume: 780,738 shs.
  • Beta: 0.79
  • Short Ratio: 28.91
 

Frequently Asked Questions for Adamas Pharmaceuticals (NASDAQ:ADMS)

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) issued its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.81) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The company's revenue for the quarter was down 90.9% on a year-over-year basis. During the same period last year, the firm earned ($0.78) EPS. View Adamas Pharmaceuticals' Earnings History.

When will Adamas Pharmaceuticals make its next earnings announcement?

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Adamas Pharmaceuticals.

Where is Adamas Pharmaceuticals' stock going? Where will Adamas Pharmaceuticals' stock price be in 2017?

6 brokerages have issued 1 year price targets for Adamas Pharmaceuticals' stock. Their predictions range from $30.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $40.80 in the next twelve months. View Analyst Ratings for Adamas Pharmaceuticals.

What are analysts saying about Adamas Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (9/21/2017)
  • 2. Mizuho analysts commented, "We updated our model post-1Q:17 and the recent royalty financing." (6/6/2017)

Are investors shorting Adamas Pharmaceuticals?

Adamas Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 6,172,830 shares, an increase of 58.0% from the August 15th total of 3,906,058 shares. Based on an average daily volume of 2,386,394 shares, the short-interest ratio is presently 2.6 days. Approximately 36.1% of the shares of the stock are sold short.

Who are some of Adamas Pharmaceuticals' key competitors?

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:

  • Gregory T. Went Ph.D., Chairman of the Board, Chief Executive Officer
  • Alfred G. Merriweather, Chief Financial Officer
  • Richard A. King, Chief Operating Officer
  • Leonie McConville, Senior Vice President - Human Resources
  • Natalie L. McClure Ph.D., Senior Vice President - Product Development
  • Jennifer J. Rhodes, Chief Compliance Officer, General Counsel, Corporate Secretary
  • Martin Forrest, Vice President, Corporate Communications and Investor Relations
  • Rajiv Patni M.D., Chief Medical Officer
  • David L. Mahoney, Lead Independent Director
  • Michael F. Bigham, Director

Who owns Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (11.02%), Vanguard Group Inc. (3.33%), Alliancebernstein L.P. (3.21%), Emerald Mutual Fund Advisers Trust (2.56%), Emerald Advisers Inc. PA (2.38%) and State Street Corp (1.27%). Company insiders that own Adamas Pharmaceuticals stock include Great Point Partners Llc, Gregory T Went, Ivan M Lieberburg, Ix Lp Mdv, Jennifer J Rhodes, Natalie Mcclure, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.

Who sold Adamas Pharmaceuticals stock? Who is selling Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Ontario Teachers Pension Plan Board, Russell Investments Group Ltd., Northern Trust Corp, California State Teachers Retirement System, Cheyne Capital Management UK LLP, Goldman Sachs Group Inc., Parametric Portfolio Associates LLC and Bank of New York Mellon Corp. Company insiders that have sold Adamas Pharmaceuticals stock in the last year include Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and William J Dawson. View Insider Buying and Selling for Adamas Pharmaceuticals.

Who bought Adamas Pharmaceuticals stock? Who is buying Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Bamco Inc. NY, Vanguard Group Inc., Granite Point Capital Management L.P., State Street Corp, Alliancebernstein L.P., Dimensional Fund Advisors LP and Emerald Advisers Inc. PA. Company insiders that have bought Adamas Pharmaceuticals stock in the last two years include Ix Lp Mdv and William W Ericson. View Insider Buying and Selling for Adamas Pharmaceuticals.

How do I buy Adamas Pharmaceuticals stock?

Shares of Adamas Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of Adamas Pharmaceuticals stock can currently be purchased for approximately $21.37.


MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  281
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Adamas Pharmaceuticals (NASDAQ:ADMS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $40.80 (90.92% upside)

Analysts' Ratings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Piper Jaffray CompaniesReiterated RatingOverweight$30.00LowView Rating Details
9/19/2017MizuhoReiterated RatingBuy -> Buy$26.00 -> $48.00HighView Rating Details
9/17/2017Needham & Company LLCReiterated RatingBuy$38.00MediumView Rating Details
8/25/2017William BlairReiterated RatingOurperformHighView Rating Details
8/25/2017JMP SecuritiesReiterated RatingMkt Outperform -> Outperform$29.00 -> $33.00HighView Rating Details
8/25/2017Cowen and CompanyReiterated RatingOutperform$45.00 -> $55.00HighView Rating Details
8/9/2017Noble FinancialReiterated RatingBuyHighView Rating Details
7/25/2016Credit Suisse GroupReiterated RatingBuy$21.00N/AView Rating Details
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Earnings by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Earnings History by Quarter for Adamas Pharmaceuticals (NASDAQ ADMS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($1.01)N/AView Earnings Details
8/8/2017Q2 2017($0.81)($0.93)$0.03 million$0.02 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.72)($0.72)$0.11 millionViewListenView Earnings Details
2/28/2017Q4($0.80)($0.68)$0.17 million$0.04 millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.83)($0.66)$0.26 million$0.14 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.71)($0.78)$0.18 million$0.22 millionViewN/AView Earnings Details
5/10/2016Q1($0.76)($0.65)$0.18 millionViewN/AView Earnings Details
2/23/2016Q4($0.81)($0.58)$0.10 million$0.52 millionViewN/AView Earnings Details
11/12/2015Q3($0.79)($0.81)$0.10 million$0.77 millionViewN/AView Earnings Details
8/11/2015Q215($0.67)($0.78)$0.10 million$0.40 millionViewN/AView Earnings Details
5/13/2015Q414($0.74)($0.69)$0.10 million$0.23 millionViewN/AView Earnings Details
3/3/2015Q4 2014$0.64$0.50$30.18 million$30.30 millionViewN/AView Earnings Details
11/4/2014Q314($0.44)($0.57)$0.18 million$0.22 millionViewN/AView Earnings Details
8/7/2014Q214$2.07$0.88$18.75 million$25.15 millionViewN/AView Earnings Details
5/13/2014Q114($0.09)($0.67)$30.60 million$0.18 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)
2017 EPS Consensus Estimate: ($3.49)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.64)($0.64)($0.64)
Q2 20171($0.84)($0.84)($0.84)
Q3 20171($0.93)($0.93)($0.93)
Q4 20171($1.08)($1.08)($1.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Insider Ownership Percentage: 29.00%
Institutional Ownership Percentage: 69.24%
Insider Trades by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Insider Trades by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/21/2017Great Point Partners LlcMajor ShareholderSell380,000$17.08$6,490,400.00View SEC Filing  
6/21/2017Jennifer J. RhodesInsiderSell1,041$17.53$18,248.73View SEC Filing  
6/19/2017Great Point Partners LlcMajor ShareholderSell350,000$17.05$5,967,500.00View SEC Filing  
3/21/2017Gregory T WentCEOSell2,807$17.03$47,803.21View SEC Filing  
3/21/2017Rajiv PatniInsiderSell733$17.04$12,490.32View SEC Filing  
3/21/2017William J DawsonCFOSell716$17.02$12,186.32View SEC Filing  
9/16/2016Ix Lp MdvMajor ShareholderBuy62,977$16.48$1,037,860.96View SEC Filing  
9/13/2016Ix Lp MdvMajor ShareholderBuy84,376$15.58$1,314,578.08View SEC Filing  
9/7/2016William W EricsonDirectorBuy60,846$15.68$954,065.28View SEC Filing  
9/6/2016Ix Lp MdvMajor ShareholderBuy50,919$14.79$753,092.01View SEC Filing  
9/6/2016William W EricsonDirectorBuy7,200$15.00$108,000.00View SEC Filing  
9/2/2016William W EricsonDirectorBuy43,719$14.75$644,855.25View SEC Filing  
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.00View SEC Filing  
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.00View SEC Filing  
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.00View SEC Filing  
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.00View SEC Filing  
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Adamas Pharmaceuticals (NASDAQ:ADMS)
Latest Headlines for Adamas Pharmaceuticals (NASDAQ:ADMS)
Source:
DateHeadline
americanbankingnews.com logoWilliam Blair Brokers Lift Earnings Estimates for Adamas Pharmaceuticals, Inc. (ADMS)
www.americanbankingnews.com - September 22 at 6:56 AM
americanbankingnews.com logoAdamas Pharmaceuticals, Inc. (ADMS) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - September 21 at 8:20 PM
americanbankingnews.com logoWilliam Blair Weighs in on Adamas Pharmaceuticals, Inc.'s FY2020 Earnings (ADMS)
www.americanbankingnews.com - September 21 at 3:56 PM
seekingalpha.com logoAdamas Releases Pricing For GOCOVRI - Seeking Alpha
seekingalpha.com - September 20 at 8:25 PM
americanbankingnews.com logoPiper Jaffray Companies Reaffirms Overweight Rating for Adamas Pharmaceuticals, Inc. (ADMS)
www.americanbankingnews.com - September 20 at 1:26 PM
americanbankingnews.com logoAdamas Pharmaceuticals' (ADMS) Buy Rating Reiterated at Mizuho
www.americanbankingnews.com - September 19 at 10:20 PM
thestreet.com logoMediWound Shares Lower After Pricing Stock Offering - Biotech Movers
www.thestreet.com - September 19 at 8:31 PM
rttnews.com logoAdamas Pharmaceuticals Inc. (ADMS) Has Broken Out To A New High For The Year
www.rttnews.com - September 19 at 8:31 PM
seekingalpha.com logoPremarket analyst action - healthcare coverage changes - Seeking Alpha
seekingalpha.com - September 19 at 3:29 PM
finance.yahoo.com logoAdamas' Parkinson's Drug Cost Is Double Analyst Expectations
finance.yahoo.com - September 19 at 3:29 PM
americanbankingnews.com logoNeedham & Company LLC Reiterates "Buy" Rating for Adamas Pharmaceuticals, Inc. (ADMS)
www.americanbankingnews.com - September 17 at 8:48 AM
americanbankingnews.com logoAdamas Pharmaceuticals, Inc. (ADMS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 9:04 PM
americanbankingnews.com logo-$1.06 EPS Expected for Adamas Pharmaceuticals, Inc. (ADMS) This Quarter
www.americanbankingnews.com - September 16 at 8:22 PM
seekingalpha.com logoAdamas Prepares For Parkinson's Launch - Seeking Alpha
seekingalpha.com - September 14 at 3:26 PM
americanbankingnews.com logoShort Interest in Adamas Pharmaceuticals, Inc. (ADMS) Rises By 58.0%
www.americanbankingnews.com - September 14 at 1:54 AM
globenewswire.com logoAdamas to Host Investor and Analyst Meeting on September 18, 2017 - GlobeNewswire (press release)
globenewswire.com - September 13 at 9:20 PM
finance.yahoo.com logoAdamas to Host Investor and Analyst Meeting on September 18, 2017
finance.yahoo.com - September 13 at 9:20 PM
americanbankingnews.com logoAdamas Pharmaceuticals' (ADMS) "Buy" Rating Reiterated at Mizuho
www.americanbankingnews.com - September 13 at 9:52 AM
streetinsider.com logoAdamas Pharma (ADMS) Reports Topline Phase 1b Data of ADS-4101 (lacosamide)
www.streetinsider.com - September 8 at 3:49 PM
streetinsider.com logoAdamas Pharma (ADMS) Reports Topline Phase 1b Data of ADS ... - StreetInsider.com
www.streetinsider.com - September 7 at 3:23 PM
streetinsider.com logoAdamas Pharma (ADMS) Reports Topline Phase 1b Data of ADS-4101 (lacosamide) - StreetInsider.com
www.streetinsider.com - September 7 at 3:23 PM
finance.yahoo.com logoAdamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
finance.yahoo.com - September 7 at 3:23 PM
finance.yahoo.com logoAdamas Announces Topline Phase 1b Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
finance.yahoo.com - September 7 at 3:23 PM
americanbankingnews.com logoAdamas Pharmaceuticals Inc (ADMS) Earns "Buy" Rating from Mizuho
www.americanbankingnews.com - September 6 at 12:16 AM
americanbankingnews.com logoAdamas Pharmaceuticals, Inc. (ADMS) Stock Rating Reaffirmed by Piper Jaffray Companies
www.americanbankingnews.com - September 4 at 4:32 PM
americanbankingnews.com logoAdamas Pharmaceuticals, Inc. (ADMS) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - September 3 at 11:58 PM
finance.yahoo.com logoETFs with exposure to Adamas Pharmaceuticals, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 8:25 PM
marketwatch.com logoAdamas Pharma says its new Parkinson's drug isn't just a more expensive, long-acting version of generic - MarketWatch
www.marketwatch.com - August 29 at 8:51 PM
marketwatch.com logoAdamas Pharma stock surges 7% after negative FDA decision for rival Acorda's Parkinson's treatment - MarketWatch
www.marketwatch.com - August 29 at 3:50 PM
finance.yahoo.com logoAdamas Pharma stock surges 7% after negative FDA decision for rival Acorda's Parkinson's treatment
finance.yahoo.com - August 29 at 3:49 PM
finance.yahoo.com logoAdamas Pharma says its new Parkinson’s drug isn’t just a more expensive, long-acting version of generic
finance.yahoo.com - August 29 at 3:49 PM
americanbankingnews.com logo Analysts Anticipate Adamas Pharmaceuticals, Inc. (ADMS) to Announce -$1.06 EPS
www.americanbankingnews.com - August 29 at 8:18 AM
rttnews.com logoAdamas Pharmaceuticals Inc. (ADMS) Surged After FDA Approval
www.rttnews.com - August 29 at 1:38 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Adamas Pharmaceuticals and XOMA Corporation
finance.yahoo.com - August 28 at 3:37 PM
finance.yahoo.com logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : August 28, 2017
finance.yahoo.com - August 28 at 3:37 PM
seekingalpha.com logoAdamas Pharmaceuticals: Still Upside After Big Rally - Seeking Alpha
seekingalpha.com - August 27 at 3:21 PM
nasdaq.com logoImplied Volatility Surging for Adamas Pharmaceuticals (ADMS ... - Nasdaq
www.nasdaq.com - August 25 at 10:03 PM
seekingalpha.com logoWhat Adamas FDA Approval Really Means - Seeking Alpha
seekingalpha.com - August 25 at 10:03 PM
streetinsider.com logoAdamas Pharma (ADMS) Reports FDA Approval of GOCOVRI for Treatment of Dyskinesia in Parkinson's Disease Patients
www.streetinsider.com - August 25 at 5:03 PM
nasdaq.com logoAdamas Pharmaceuticals Inc. (ADMS) Has Leaped To A New High After FDA Approval
www.nasdaq.com - August 25 at 5:03 PM
finance.yahoo.com logoJackson Hole has the dollar on ‘the edge of a cliff’ — here’s how to play its next move
finance.yahoo.com - August 25 at 5:03 PM
finance.yahoo.com logo'Date' These Potential Biotech Winners
finance.yahoo.com - August 25 at 5:03 PM
finance.yahoo.com logoAdamas Skyrockets on FDA Approval for Dyskinesia Treatment - Biotech Movers
finance.yahoo.com - August 25 at 5:03 PM
finance.yahoo.com logoAdamas Pharmaceuticals (ADMS) Stock Soars 41% After FDA Approval
finance.yahoo.com - August 25 at 5:02 PM
americanbankingnews.com logoAdamas Pharmaceuticals' (ADMS) "Ourperform" Rating Reiterated at William Blair
www.americanbankingnews.com - August 25 at 11:42 AM
americanbankingnews.com logoAdamas Pharmaceuticals, Inc. (ADMS) Earns "Outperform" Rating from JMP Securities
www.americanbankingnews.com - August 25 at 9:42 AM
americanbankingnews.com logoCowen and Company Reiterates Outperform Rating for Adamas Pharmaceuticals, Inc. (ADMS)
www.americanbankingnews.com - August 25 at 9:42 AM
finance.yahoo.com logoAdamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
finance.yahoo.com - August 24 at 8:28 PM
finance.yahoo.com logoAdamas Pharma shares soar on Parkinson's dyskinesia drug approval
finance.yahoo.com - August 24 at 8:28 PM
finance.yahoo.com logoAdamas Pharmaceuticals, Inc. :ADMS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 3:26 PM

Social

Chart

Adamas Pharmaceuticals (ADMS) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff